

JGWS 12 NOV 2003

ROPES
& GRAY

ROPES & GRAY LLP

ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624 617-951-7000 F 617-951-7050
BOSTON NEW YORK SAN FRANCISCO WASHINGTON, DCFAX TRANSMITTAL LETTER**IMPORTANT:** PLEASE DELIVER THIS DOCUMENT IMMEDIATELY!

IF YOU DO NOT RECEIVE ALL PAGES, PLEASE CALL: (617) 951-7000

TOTAL NUMBER OF PAGES INCLUDING THIS TRANSMITTAL LETTER: ~~8~~ 7

<u>Name</u>	<u>Firm/Company</u>	<u>Fax Number</u>	<u>Phone Number</u>
To: Office of Initial Patent Examination's Filing Receipt Corrections	Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313- 1450	(703) 746-9195	

From: David P. Halstead

Re: Applicant: Andrew Mortlock et al. Art Unit: 1614
Serial No.: 10/088,814
Filing Date: September 4, 2002
Title: QUINAZOLINE DERIVATIVES AND THEIR USE AS
PHARMACEUTICALS

Comments: We have yet to receive the Corrected Filing Receipt which we have requested on May 22, 2003 (Original request and fax confirmation are attached). We respectfully request your attention to this matter. Thank you.

PLEASE COMPLETE WHEN SUBMITTING TO FAX DEPARTMENT

Date: November 10, 2003

Time:

File Symbol: ASZD-P01-599

Personal ID Number: 28436

Submitted By: David P. Halstead

Phone: (617) 951-7615

THIS FAX MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE. IT IS INTENDED FOR USE ONLY BY THOSE TO WHOM IT IS ADDRESSED. IF THIS FAX IS NOT ADDRESSED TO YOU, OR IF YOU RECEIVED IT IN ERROR, YOU MAY NOT DISCLOSE, DISTRIBUTE, COPY OR USE THIS FAX OR ANY INFORMATION IN IT. INSTEAD, PLEASE CALL US COLLECT AT (617) 951-7000 TO ARRANGE FOR ITS DESTRUCTION OR RETURN.

NOV-10-2003 18:07

ROPES & GRAY

P.02

***** -COMM. JOURNAL ***** DATE MAY-22- 03 ***** TIME 13:53 ***** P.01

MODE = TRANSMISSION

START=MAY-22 13:51

END=MAY-22 13:53

STN NO.	COM	ABBR NO.	STATION NAME/TEL.NO.	PAGES	DURATION
001	OK	*	917037469195	005	00:02'08"

-ROPES & GRAY

-

- *****

- *****



ROPES & GRAY LLP

ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624 617-951-7000 F 617-951-7050
BOSTON NEW YORK SAN FRANCISCO WASHINGTON, DC**FAX TRANSMITTAL LETTER****IMPORTANT:** PLEASE DELIVER THIS DOCUMENT IMMEDIATELY!

IF YOU DO NOT RECEIVE ALL PAGES, PLEASE CALL: (617) 951-7000

TOTAL NUMBER OF PAGES INCLUDING THIS TRANSMITTAL LETTER: 4

<u>Name</u>	<u>Firm/Company</u>	<u>Fax Number</u>	<u>Phone Number</u>
To: Office of Initial Patent Examination's Filing Receipt Corrections	Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313- 1450	(703) 746-9195	

From: David P. Halstead

Re: Applicant: Andrew Mortlock et al. Art Unit: 1614
Serial No.: 10/088,814
Filing Date: September 4, 2002
Title: QUINAZOLINE DERIVATIVES AND THEIR USE AS
PHARMACEUTICALS

Attached: Request for Corrected Filing Receipt (1 page); copy of incorrect Filing Receipt (2
pages); copy of cover page of priority document (1 page)

PLEASE COMPLETE WHEN SUBMITTING TO FAX DEPARTMENT

Date: May 22, 2003

File Symbol: ASZD-P01-599

Submitted By: David P. Halstead

Time:

Personal ID Number: 28436

Phone: (617) 951-7615

THIS FAX MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE.
IT IS INTENDED FOR USE ONLY BY THOSE TO WHOM IT IS ADDRESSED. IF THIS FAX IS NOT ADDRESSED TO
YOU, OR IF YOU RECEIVED IT IN ERROR, YOU MAY NOT DISCLOSE, DISTRIBUTE, COPY OR USE THIS FAX OR ANY
INFORMATION IN IT. INSTEAD, PLEASE CALL US COLLECT AT (617) 951-7000 TO ARRANGE FOR ITS
DESTRUCTION OR RETURN

I hereby certify that this correspondence being telefaxed to the U.S. Patent Office, Office of Initial Patent Examination's Filing Receipt Corrections at Facsimile No. (703) 748-9165, on the date shown below.	
Dated: <u>May 22, 2003</u>	Signature: <u>Mary Jane DiPalma</u> (Mary Jane DiPalma)

Docket No.: ASZD-P01-599
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mortlock et al.

Application No.: 10/088,814

Group Art Unit: 1614

Filing Date: September 4, 2002

Examiner: Not Yet Assigned

For: QUINAZOLINE DERIVATIVES AND THEIR
USE AS PHARMACEUTICALS

REQUEST FOR CORRECTED FILING RECEIPT

Office of Initial Patent Examination's Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request that a corrected Filing Receipt be issued in the above-identified patent application as follows:

Under Foreign Applications

Please correct the second United Kingdom application no. from "9922145.1" to --
9922154.1--.

Applicants enclose a copy of incorrect Filing Receipt with the changes noted thereon and a copy of the first page of the priority document noting the correct priority data.

Applicants additionally request that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect these corrections.

Dated: May 22, 2003

Respectfully submitted,

By David P. Halstead
David P. Halstead
Registration No.: 44,735
Attorneys/Agents For Applicant

Customer No.: 28120
Docketing Specialist
Ropes & Gray LLP
One International Place
Boston, MA 02110
Phone (617) 951-7615
Fax: (617) 951-7050

Intellectual Property Dept.

MAY 19 2003



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/088,814	09/04/2002	1614	1570	ASZD-P01-599		31	2

CONFIRMATION NO. 2356

28120

ROPES & GRAY LLP
 ONE INTERNATIONAL PLACE
 BOSTON, MA 02110-2624

FILING RECEIPT

OC00000000998449

Date Mailed: 05/13/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Andrew Austen Mortlock, Macclesfield Cheshire, UNITED KINGDOM;
 Nicholas John Keen, Macclesfield Cheshire, UNITED KINGDOM;
 Frederic Henri Jung, Reims, FRANCE;
 Andrew George Brewster, Paris, FRANCE;

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB00/03580 09/18/2000

Foreign Applications

UNITED KINGDOM 9922170.7 09/21/1999
 UNITED KINGDOM 9922145.1 09/21/1999
 9922154.1

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

Title

Quinazoline derivatives and th ir use as pharmaceuticals

R&G

Docket No.:

ASZD-P01-599

Action:

review assignment

Stat. Deadline:

7/19/03

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21596: A1(51) International Patent Classification⁷: C07D 239/94,
A61K 31/517, A61P 35/00

(21) International Application Number: PCT/GB00/03580

(22) International Filing Date:
18 September 2000 (18.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9922170.7 21 September 1999 (21.09.1999) GB
9922154.1 21 September 1999 (21.09.1999) GB(71) Applicant (for all designated States except MG, US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Sodertalje (SE).(71) Applicant (for MG only): ASTRAZENECA UK LIM-
ITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN
(GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): MORTLOCK,
Andrew, Austen [GB/GB]; Alderley Park, Maccles-
field, Cheshire SK10 4TG (GB). KEEN, Nicholas,John [GB/GB]; Alderley Park, Macclesfield, Cheshire
SK10 4TG (GB). JUNG, Frederic, Henri [FR/FR]; Z.I.
la Pompelle, BP1050, F-51689 Reims Cedex 2 (FR).
BREWSTER, Andrew, George [GB/FR]; 7, rue au
Metre, F-78290 Croissy-sur-Seine (FR).(74) Agent: BRYANT, Tracey; Astrazeneca, Global Intellec-
tual Property, P.O. Box 272, Merseyside, Alderley Park, Mac-
clesfield, Cheshire SK10 4GR (GB).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

[Continued on next page]

(54) Title: QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS



(I)

(57) Abstract: The use of a compound of formula (I) or a salt, ester, amide or prodrug thereof; where X is O, or S, S(O) or S(O)₂, NH or NR¹² where R¹² is hydrogen or C₁₋₆ alkyl; R⁵ is selected from a group NHC(O)OR⁹, NHC(O)R⁹, NHS(O)₂R⁹, C(O)R⁹, C(O)OR⁹, S(O)R⁹, S(O)OR⁹, S(O)₂OR⁹, C(O)NR¹⁰R¹¹, S(O)NR¹⁰R¹¹, S(O)ONR¹⁰R¹¹, where R⁹, R¹⁰ or R¹¹ are various specified organic groups; R⁶ is hydrogen, optionally substituted hydrocarbonyl or optionally substituted heterocyclyl; R⁷ and R⁸ are various specified organic groups, and R¹, R², R³, R⁴ are independently selected from halogeno, cyano, nitro, C₁₋₆alkylsulphonyl, -N(OH)R¹³, (wherein R¹³ is hydrogen, or C₁₋₆alkyl), or R¹⁵X¹-(wherein X¹ represents a direct bond, -O-, -CH₂-, -OCO-, carbonyl, -S-, -SO-, -SO₂-, -CONR¹⁶-, -SO₂NR¹⁶-, -NR¹⁷SO₂- or -NR¹⁸-(wherein R¹⁶, R¹⁷ and R¹⁸ each independently represents hydrogen, or C₁₋₆alkyl, or C₁₋₆alkylsulphonyl, or optionally substituted heterocyclyl) or op-